SBMFF (Sino Biopharmaceutical) Total Liabilities: $4,817 Mil (As of Dec. 2025)

What is Sino Biopharmaceutical Total Liabilities?

Sino Biopharmaceutical SBMFF -1.48% 61 Total Liabilities is $4,817 Mil as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.60 (Fairly Valued). The stock has 4 warning signs investors should review.

Sino Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2025 was $4,817 Mil.

Sino Biopharmaceutical's quarterly Total Liabilities increased from Dec. 2024 ($3,108.77 Mil) to Jun. 2025 ($4,055.02 Mil) and increased from Jun. 2025 ($4,055.02 Mil) to Dec. 2025 ($4,816.55 Mil).

Sino Biopharmaceutical's annual Total Liabilities declined from Dec. 2023 ($3,562.21 Mil) to Dec. 2024 ($3,108.77 Mil) but then increased from Dec. 2024 ($3,108.77 Mil) to Dec. 2025 ($4,816.55 Mil).

Sino Biopharmaceutical Total Liabilities Related Terms

Sino Biopharmaceutical Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Total Liabilities Chart

Sino Biopharmaceutical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

3,581.92

3,746.68

3,562.21

3,108.77

4,816.55

Sino Biopharmaceutical Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Liabilities	Get a 7-Day Free Trial															3,562.21	3,388.43	3,108.77	4,055.02	4,816.55

61GF Score

Sino Biopharmaceutical Ltd SBMFF

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sino Biopharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sino Biopharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3577.858	+	(1086.337	+	152.351
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4,817

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	10791.944	-	5975.399
	=	4,817

Sino Biopharmaceutical's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3577.858	+	(1086.337	+	152.351
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4,817

Total Liabilities	=	Total Assets (Q: Dec. 2025 )	-	Total Equity (Q: Dec. 2025 )
	=	10791.944	-	5975.399
	=	4,817

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $4,817 Mil mean?

Sino Biopharmaceutical (SBMFF) has a Total Liabilities of $4,817 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sino Biopharmaceutical and its competitors.

Is Sino Biopharmaceutical's Total Liabilities too high?

Sino Biopharmaceutical's current Total Liabilities is $4,817 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Sino Biopharmaceutical's Total Liabilities compare to VRTX and REGN?

Sino Biopharmaceutical's Total Liabilities of $4,817 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Total Liabilities is $4,817 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sino Biopharmaceutical stock overvalued right now?

Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.60, compared to a current price of $0.59 — trading 1.2% below its estimated fair value. The current Total Liabilities is $4,817 Mil. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Total Liabilities is $4,817 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $0.59 is trading 1.2% below its estimated GF Value™ of $0.60. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for SBMFF:

Total Liabilities: $4,817 Mil
GF Value™: $0.60 vs. price of $0.59 (1.2% below fair value)
GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sino Biopharmaceutical Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:09926 HKSE:09995 HKSE:06990 HKSE:02315 HKSE:01530 HKSE:02696 HKSE:01877 HKSE:01548 HKSE:09969 HKSE:01801 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SBHMY:USA SINOBIO19:Thailand 01177:Hong Kong SMZ1:Germany

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website https://www.sbpgroup.com

Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.

61GF Score

Get the complete analysis for SBMFF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59

Price

$0.60

GF Value

View SBMFF Analysis

See Total Liabilities data for all stocks →